<DOC>
	<DOCNO>NCT01797848</DOCNO>
	<brief_summary>The purpose study determine whether 24 week treatment Daclatasvir ( DCV ) combination Pegylated-interferon alfa 2a ( pegIFNα-2a ) Ribavirin ( RBV ) safe demonstrate rate Sustained Virologic Response follow week 24 ( SVR24 ) ( define undetectable HCV RNA post-treatment Week 24 ) non-inferior 48 week dual combination therapy pegIFNα-2a/RBV majority study subject</brief_summary>
	<brief_title>Efficacy Safety Evaluation Treatment Consisting Peg Interferon Alfa + Ribavirin + Daclatasvir HCV Genotype 1 4 Treatment naïve Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients chronically infect Hepatitis C virus ( HCV ) GT 1 4 HCV RNA viral load ≥ 10,000 IU/mL Naïve prior treatment interferon formulation , Ribavirin ( RBV ) HCV direct antiviral agent Patients compensate cirrhosis permit Infected HCV GT 1 4 Evidence decompensated liver disease Documented suspect Hepatocellular carcinoma ( HCC ) evidence previously obtain image study liver biopsy Evidence medical condition contribute chronic liver disease HCV History chronic Hepatitis B virus ( HBV ) Human immunodeficiency virus ( HIV ) Current know history cancer ( except situ carcinoma cervix adequately treat basal squamous cell carcinoma skin ) within 5 year prior enrollment Laboratory value : 1 . Hemoglobin &lt; 12 g/dL ( female ) &lt; 13 g/dL ( male ) 2 . Platelets &lt; 90 x 1000000000 cells/L 3 . Absolute neutrophil count ( ANC ) &lt; 1.5 × 1000000000 cells/L 4 . Total bilirubin ≥ 34 µmol/L ( unless due Gilbert 's disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>